SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) today announced that data featuring its approved drugs and pipeline candidates will be presented at the 66th Annual Scientific Sessions of the American Diabetes Association (ADA) being held in Washington, DC from June 9 to 13. The company will also host an investor conference during the meeting that will be available by webcast. ADA is one of the largest scientific meetings for endocrinologists and other health care professionals involved in diabetes research and the delivery of diabetes care.
